Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study. - Zou; Tang X; Deng P; Liu Y; Yang T; Tan X; Yang L; Li W; Zeng X (Breast cancer research : BCR, 2026)